|| Checking for direct PDF access through Ovid
Haemorrhagicproctitis remains a challenging disorder because of its chronic and refractoryprogress in inflammatory bowel disease or after radiation. Surgical and conservative treatment options are available butprospective and randomised data are missing.We retrospectively evaluated the clinical data and outcome of patients with haemorrhagicproctitis at our coloproctology unit from 2005-2008.Seventy-nine patients (53 male, 26 female) with haemorrhagicproctitis were treated in our clinic. Postradiogenicproctitis was most frequently observed in 59 (75%), ulcerativeproctitis in 8 (10%) and unspecificproctitis in seven patients (9%). First-line treatment was topical administration of corticosteroids, mesalazine and mebeverinhydrochloride (with use of suppositories or clysma). Additionally sucralfat clysma was used off-label in 50% of the patients. In 13 (16.5%) patients topical application of 4% formaldehyde was used in case of refractory bleeding. No surgical complication has been observed in the mid-term follow-up.With the burden ofprostate carcinoma incidence of refractory radiogenicproctitis has increased in the last years. The administration of topical steroids and systemic salicylic-acid derivates as well as sucralfat clysma can be used forprimary treatment. Alternative options are topical formaldehyde in refractory haemorrhagicproctitis.